Zai Lab (NASDAQ:ZLAB) Director William Lis Sells 7,040 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Director William Lis sold 7,040 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $18.09, for a total transaction of $127,353.60. Following the transaction, the director owned 50,437 shares of the company’s stock, valued at approximately $912,405.33. This trade represents a 12.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Zai Lab Price Performance

Shares of ZLAB traded down $0.12 during mid-day trading on Wednesday, hitting $18.37. The company’s stock had a trading volume of 1,131,581 shares, compared to its average volume of 812,523. The firm has a 50-day moving average price of $19.63 and a 200 day moving average price of $18.98. Zai Lab Limited Unsponsored ADR has a fifty-two week low of $15.96 and a fifty-two week high of $41.20. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -11.34 and a beta of 0.78.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings results on Wednesday, April 1st. The company reported ($0.50) earnings per share (EPS) for the quarter. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. The company had revenue of $99.61 million during the quarter. As a group, equities analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ZLAB shares. Weiss Ratings lowered Zai Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 4th. Wall Street Zen cut Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Citigroup cut their target price on shares of Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. JPMorgan Chase & Co. lowered their price target on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a report on Wednesday, March 18th. Finally, Cantor Fitzgerald dropped their price target on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $45.83.

Hedge Funds Weigh In On Zai Lab

An institutional investor recently raised its stake in Zai Lab stock. SG Americas Securities LLC boosted its holdings in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the quarter. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 at the end of the most recent reporting period. 41.65% of the stock is owned by institutional investors and hedge funds.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.